WuXi AppTec, a leading global provider of R&D and manufacturing services for the pharmaceutical and life sciences industries, has been named to the FTSE4Good Index Series for the second consecutive year. This recognition highlights WuXi AppTec’s strong performance in environmental, social, and governance (ESG) practices, reflecting its dedication to sustainability and innovation for a healthier world.
The FTSE4Good Index Series, created by FTSE Russell, tracks companies with robust ESG practices, evaluating them on criteria such as Corporate Governance, Health & Safety, Anti-Corruption, and Climate Change. WuXi AppTec’s inclusion in this index underscores its commitment to surpassing global industry standards in ESG performance.
Edward Hu, Vice Chairman of WuXi AppTec and Chairman of the ESG Committee, expressed pride in this recognition, stating, “We are thrilled to be acknowledged by the FTSE4Good Index Series for our ESG achievements. Our commitment to ESG initiatives and sustainable operations remains a core focus as we deliver innovative therapies worldwide. Our CRDMO and CTDMO business models enable us to support customer needs effectively while working towards a healthier and more sustainable future.”
WuXi AppTec, a key player in the pharmaceutical and life sciences sectors, integrates ESG priorities throughout its operations. In 2024, the company joined the United Nations Global Compact and the Science Based Targets initiative to enhance its sustainability efforts. It was also named to the S&P Global Sustainability Yearbook and recognized by Sustainalytics as an Industry and Regional “Top-Rated” company. WuXi AppTec’s ESG performance has been acknowledged by major global rating agencies, including MSCI, CDP, and EcoVadis.
WuXi AppTec
WuXi AppTec operates globally across Asia, Europe, and North America, offering a wide range of R&D and manufacturing services that advance the pharmaceutical and life sciences industries. Its integrated services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing, and clinical research. The company also offers advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization) to enhance the efficiency and cost-effectiveness of healthcare product development. WuXi AppTec received an AA ESG rating from MSCI for the third consecutive year in 2023 and serves over 6,000 customers from more than 30 countries, working towards its vision that “every drug can be made and every disease can be treated.
